drugset / Trial / NCT00440557

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

NCT00440557

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate that once weekly and once every-2-weeks treatment with epoetin alfa, in patients with anemia associated with chronic kidney disease, is not less effective than the approved treatment with epoetin alfa that is given 3 times weekly with respect to changes in hemoglobin.

Timeline

Start
2006-09
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 50 iu/kg Subcutaneous
Subject epoetin alfa Protein / enzyme biologic 10000 iu Subcutaneous
Subject epoetin alfa Protein / enzyme biologic 20000 iu Subcutaneous

Indications